$6.34
0.48% yesterday
NYSE, Sep 03, 10:00 pm CET
ISIN
US05153U1079
Symbol
AURA

Aura Biosciences Stock price

$6.34
-0.27 4.08% 1M
-0.87 12.07% 6M
-1.88 22.87% YTD
-1.05 14.21% 1Y
-6.76 51.60% 3Y
-8.46 57.16% 5Y
-8.46 57.16% 10Y
-8.46 57.16% 20Y
NYSE, Closing price Wed, Sep 03 2025
+0.03 0.48%
ISIN
US05153U1079
Symbol
AURA
Industry

Key metrics

Basic
Market capitalization
$393.8m
Enterprise Value
$216.5m
Net debt
positive
Cash
$177.3m
Shares outstanding
62.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.3
Financial Health
Equity Ratio
83.3%
Return on Equity
-57.2%
ROCE
-57.3%
ROIC
-430.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-107.5m | -
EBIT
$-108.7m | $-122.1m
Net Income
$-101.4m | $-131.6m
Free Cash Flow
$-84.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-20.7% | -
EBIT
-20.3% | -27.1%
Net Income
-25.7% | -51.4%
Free Cash Flow
-13.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.7
FCF per Share
$-1.4
Short interest
5.0%
Employees
108
Rev per Employee
$0.0
Show more

Is Aura Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Aura Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Aura Biosciences forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Aura Biosciences forecast:

Buy
92%
Hold
8%

Financial data from Aura Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
11% 11%
-
- Research and Development Expense 86 86
23% 23%
-
-108 -108
21% 21%
-
- Depreciation and Amortization 1.18 1.18
8% 8%
-
EBIT (Operating Income) EBIT -109 -109
20% 20%
-
Net Profit -101 -101
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aura Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aura Biosciences Stock News

Neutral
GlobeNewsWire
about 22 hours ago
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025, at 11:...
Neutral
GlobeNewsWire
22 days ago
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC)
Neutral
GlobeNewsWire
4 months ago
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 s...
More Aura Biosciences News

Company Profile

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Head office United States
CEO Elisabet Pinos
Employees 108
Founded 2007
Website aurabiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today